Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 23 October 2013
A new legislative draft report posted by the European Parliament's Committee on the Environment, Public Health and Food Safety (ENVI) on 18 October 2013 calls for changes to be made to the way in which user fees are payable to the European Medicines Agency (EMA) for some application filings.
EMA, like the US Food and Drug Administration (FDA), partially funds its review work through user fees payable to the agency for many routine activities, such as the registration of facilities and acceptance of applications.
Now ENVI is proposing to increase the list of activities on which a fee can be demanded by regulators, including several activities called for under last year's pharmacovigilance legislation.
In one area, legislators clarified that the size of a drug unit should not be taken into consideration for the purposes of assessing a user fee. "Whether the pack contains 10 or 20 tablets is not relevant for Pharmacovigilance," ENVI legislators wrote. "It would be more appropriate to charge according to the number of authorizations per active ingredient, and per pharmaceutical form (i.e. whether the product is a spray, a tablet or an injectable solution)."
Importantly, the user fees will now fully cover generic medicinal products for the purposes of pharmacovigilance, which will no longer be eligible for a "reduced annual flat fee."
The EU Commission has been pushing for a reduction in fees because "those products generally have a well-established safety profile." ENVI gave no reason for the change.
Elsewhere in the draft amendments text, ENVI has called for a variable fee assessment, noting that procedures can be simple or complex. "Instead of charging the same average fee whatever the workload involved, a more cost-based approach would be to move to a tiered system."
"As discussions are still ongoing about how many hours work are involved per active substance, the exact amounts are not yet included in this draft report," ENVI added.
Another area set to see changes will be signal detection fees. ENVI has proposed charging a yearly flat fee on pharmacovigilance activities and monitoring of medical literature. However, signal detection activities-unless they occur at the EU-wide level-will fall to member states, which may still charge fees.
ENVI Draft Report
Tags: Draft Report, ENVI, User Fees, Latest News, EU, pharmacovigilance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.